advisorsecurities master

DFTXDefinium Therapeutics, Inc. Common Shares

CSNasdaq (XNAS)·USD

Identity

Security key
14190
Ticker
DFTX
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2020-03-03
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
DFTX

Detail

Enriched 2026-08-14 20:47

Market cap
$5,749,561,790.5
Shares outstanding (class)
134,366,950
Shares outstanding (weighted)
134,366,950
SIC
2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees
106
Location
NEW YORK, NY
Description

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data